DelMar to present new data on development of VAL-083 at 2015 ASCO Annual Meeting

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), today announced that it will be presenting new data related to the development of lead product candidate VAL-083 (dianhydrogalactitol) at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29-June 2, 2015, in Chicago, Illinois.

The Company's clinical data from its Phase I/II study of VAL-083 (dianhydrogalactitol) in patients with refractory glioblastoma multiforme (GBM), entitled, "Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioma," (abstract no. 2023) will be presented at ASCO during the Central Nervous System Tumors poster session on Monday, June 1, 2015 being held from 1:15 p.m. - 4:45 p.m. CDT.

A second abstract, entitled, "Activity of Dianhydrogalactitol Alone or with Platinum Drugs Against Non-small Cell Lung Cancer Cell Lines," (abstract no. e19145) will be published online at and

SOURCE DelMar Pharmaceuticals, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Machine learning applications for the diagnosis, treatment and prognosis of cancer